A multi-center, randomized study, the MADIT-CRT (CRT with ICD vs. ICD only), suggests that galectin-3 might identify the highest risk HF patients who may derive the greatest absolute benefit from CRT-D therapy [30]. The gene discussed is LGALS3; the disease is hydrops fetalis.